A5006388466- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Iron Metabolism and Disorders
- Erythropoietin and Anemia Treatment
- Peptidase Inhibition and Analysis
- Heart Failure Treatment and Management
- Mast cells and histamine
- Hemophilia Treatment and Research
- Hemoglobinopathies and Related Disorders
- Social Policies and Family
- Vitamin K Research Studies
- PI3K/AKT/mTOR signaling in cancer
- Autoimmune Bullous Skin Diseases
- Potassium and Related Disorders
- Urticaria and Related Conditions
- Social Sciences and Governance
- Chronic Myeloid Leukemia Treatments
- Corporate Governance and Law
- Protease and Inhibitor Mechanisms
- T-cell and Retrovirus Studies
- Folate and B Vitamins Research
- Parathyroid Disorders and Treatments
- Membrane-based Ion Separation Techniques
- Fluoride Effects and Removal
- Financial Reporting and Valuation Research
- Dental Erosion and Treatment
Vifor Pharma (Switzerland)
2016-2023
Zimmer Biomet (Switzerland)
2020
Hospital Materno-Infantil
2016
Hospital Infantil Universitario Niño Jesús
2016
Hospital La Paz Institute for Health Research
2016
Centre for Biomedical Network Research on Rare Diseases
2016
Hospital General Nuestra Señora del Prado
2016
Complejo Hospitalario Universitario de Santiago
2016
Federico II University Hospital
2016
Universidad Rey Juan Carlos
2016
Abstract Aims To investigate the impact of patiromer on serum potassium level and its ability to enable specified target doses renin–angiotensin–aldosterone system inhibitor (RAASi) use in patients with heart failure reduced ejection fraction (HFrEF). Methods results A total 1642 HFrEF current or a history RAASi-related hyperkalemia were screened 1195 enrolled run-in phase optimization RAASi therapy [≥50% recommended dose angiotensin-converting enzyme inhibitor/angiotensin receptor...
Background Attacks of hereditary angioedema (HAE) are unpredictable and, if affecting the upper airway, can be lethal. Icatibant is used for physician- or patient self-administered symptomatic treatment HAE attacks in adults. Its mode action includes disruption bradykinin pathway via blockade B2 receptor. Early believed to shorten attack duration and prevent severe outcomes; however, evidence support these benefits lacking. Objective To examine impact timing icatibant administration on...
Hereditary angioedema (HAE) is a rare, debilitating, and potentially life-threatening disease characterized by recurrent edema attacks. Important advances in HAE treatment have been made, including the development of new therapies for treating or preventing Nevertheless, still frequently misdiagnosed inappropriately treated, exposing patients with laryngeal attacks to risk asphyxiation.The Icatibant Outcome Survey (IOS) an international, observational study that documents clinical outcome...
Patients with heart failure (HF) and iron deficiency experience poor health-related quality of life (HRQoL). We evaluated the impact intravenous (IV) ferric carboxymaltose (FCM) vs. placebo on HRQoL for AFFIRM-AHF population.The baseline 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12), which was completed 1058 (535 523) patients in FCM groups, respectively, administered prior to randomization at Weeks 2, 4, 6, 12, 24, 36, 52. The KCCQ-12 overall summary score (OSS) mean ± standard...
<h2>Abstract</h2><h3>Background</h3> Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) causes swelling in the skin and upper airways pain abdomen because of mucosal swelling. C1-INH-HAE is frequently misdiagnosed, leading delays diagnosis, inadequate treatment, unnecessary procedures. <h3>Objective</h3> To evaluate history misdiagnosis patients participating Icatibant Outcome Survey (IOS). <h3>Methods</h3> The IOS an observational study which safety effectiveness icatibant...
Aims In AFFIRM‐AHF, intravenous ferric carboxymaltose (FCM) reduced heart failure (HF) hospitalisations and improved quality of life versus placebo in iron‐deficient patients stabilised after an acute HF episode. This analysis explored the effects FCM with ischaemic non‐ischaemic aetiology. Methods results We included 1082 from AFFIRM‐AHF: 590 (defined as investigator‐reported aetiology and/or prior myocardial infarction coronary revascularisation) 492 HF. The prevalences male sex,...
Iron deficiency, with or without anemia, is an adverse prognostic factor in heart failure (HF). In AFFIRM-AHF (a randomized, double-blind placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalizations and mortality iron-deficient subjects admitted for acute failure), (FCM), although having no significant primary end point, reduced risk HF hospitalization (hHF) improved quality life versus placebo patients stabilized after (AHF) episode. These...
<b><i>Background:</i></b> Icatibant, a selective bradykinin B2 receptor antagonist for the treatment of acute hereditary angio-oedema (HAE) attacks in adults, can be administered by health care professionals (HCPs) or self-administered. This analysis compared characteristics and outcomes HAE treated with self-administered HCP-administered icatibant real-world setting. <b><i>Methods:</i></b> The Icatibant Outcome Survey (Shire, Zug, Switzerland;...
Intravenous ferric carboxymaltose (FCM) has been shown to improve overall quality of life in iron-deficient heart failure with reduced ejection fraction (HFrEF) patients at a trial population level. This FAIR-HF and CONFIRM-HF pooled analysis explored the likelihood individual improvement or deterioration Kansas City Cardiomyopathy Questionnaire (KCCQ) domains FCM versus placebo evaluated stability this response over time.Changes baseline KCCQ summary score (OSS), clinical (CSS) total...
Icatibant is used to treat acute hereditary angioedema with C1 inhibitor deficiency types I/II (C1-INH-HAE I/II) and has shown promise in due acquired (C1-INH-AAE). Data from the Outcome Survey (IOS) were analysed evaluate effectiveness of icatibant treatment patients C1-INH-AAE compare disease characteristics those C1-INH-HAE I/II. Key medical history (including prior occurrence attacks) was recorded upon IOS enrolment. Thereafter, data retrospectively at approximately 6-month intervals...
Abstract Introduction The clinical characteristics and icatibant‐treatment outcomes of patients with hereditary angioedema normal C1 inhibitor (HAE‐nC1 INH) are limited. Methods We retrospectively analyzed data from French HAE enrolled in the Icatibant Outcome Survey registry (from July 2009 to September 2013) compare disease effectiveness safety acute icatibant‐treated attacks HAE‐nC1 INH, INH deficiency (type I), or dysfunction II). Results One center Grenoble contributed 22 a family...
Ferric carboxymaltose (FCM) has been shown to achieve rapid replenishment of iron stores and correction anaemia in various populations with deficiency. A decrease serum phosphate (PO43-) levels, which most cases is asymptomatic, reported IV preparations. Hypophosphataemia (HP) a known adverse drug reaction FCM. This post hoc pooled analysis investigates the frequency, duration, risk factors, clinical signs HP as interventional trials Pooled data from subjects enrolled across 45 different...
Improving functional capacity is a key goal in heart failure (HF). This pooled analysis of FAIR-HF and CONFIRM-HF assessed the likelihood improvement or deterioration 6-min walk test (6MWT) among iron-deficient patients with chronic HF reduced ejection fraction (HFrEF) receiving ferric carboxymaltose (FCM).Data for 760 (FCM: n = 454; placebo: 306) were analysed. The proportions FCM placebo who had ≥20, ≥30, ≥40 m improvements ≥10 6MWT at 12 24 weeks assessed. Patients experienced mean...
Icatibant was efficacious and generally well tolerated for type I or II hereditary angioedema (HAE) attacks in adults the phase III, randomized, placebo-controlled For Angioedema Subcutaneous Treatment (FAST)-3 trial. The Outcome Survey (IOS) is an international, observational study assessing icatibant treatment of HAE attacks. We conducted a posthoc analysis to compare first time patients prescribed real-world versus controlled trial settings (FAST-3). In FAST-3, received administered by...
Phase 3 icatibant trials showed that most hereditary angioedema (HAE) (C1 inhibitor deficiency) acute attacks were treated successfully with one injection of icatibant, a selective bradykinin B2 receptor antagonist. We conducted post hoc analysis reinjection for HAE type I and II in real-world setting by using data from the Icatibant Outcome Survey, an ongoing observational study monitors safety effectiveness treatment.Descriptive retrospective analyses performed on Survey (February 2008 to...
The Icatibant Outcome Survey (IOS) is an observational study monitoring safety and effectiveness of icatibant in the real-world setting. We analyzed data from 3025 icatibant-treated attacks 557 patients (enrolled between July 2009 February 2015). was generally well tolerated. Excluding off-label use pregnancy, 438 (78.6%) did not report adverse events (AEs). remaining 119 (21.4%) reported 341 AEs, primarily gastrointestinal disorders (19.6%). Of these, 43 AEs 17 (3.1%) were related to...
Abstract The 9‐year‐old group (236 children) of an epidemiological study carried out in 1991 Strasbourg on children aged 6 to 15 years was selected with the aim determining if caries prevalence reduction observed could be related use salt fluoridation (FS) introduced France 1987. From these 236 children, 143 answered a questionnaire which showed that 36 them were fluoridated users and 107 not. dft index significantly lower FS consumers 35.5% compared non‐FS‐consuming children. When using...
Hereditary angioedema (HAE) is a potentially life-threatening, bradykinin-mediated disease, often misdiagnosed and under-treated, with long diagnostic delays. There are limited real-world data on best-practice management of HAE in the UK.To characterize clinical profile, outcomes patients type I II from three specialist centres UK using Icatibant Outcome Survey (IOS; Shire, Zug, Switzerland), an international observational study monitoring safety effectiveness icatibant, selective bradykinin...
Objective To characterize the management and outcomes of life-threatening laryngeal attacks hereditary angioedema (HAE) treated with icatibant in observational Icatibant Outcome Survey (NCT01034969) registry. Methods This retrospective analysis was based on data from patients HAE type I/II who received healthcare professional-administered or self-administered to treat between September 2008 May 2013. Results Twenty centers seven countries contributed data. Overall, 42 experienced 67...
Background: Attacks of hereditary angioedema (HAE) are unpredictable and, if affecting the upper airway, can be lethal.Icatibant is used for physician-or patient self-administered symptomatic treatment HAE attacks in adults.Its mode action includes disruption bradykinin pathway via blockade B 2 receptor.Early believed to shorten attack duration and prevent severe outcomes; however, evidence support these benefits lacking.Objective: To examine impact timing icatibant administration on...
Abstract Background In AFFIRM-AHF, treatment of iron deficiency with intravenous ferric carboxymaltose (FCM) reduced the risk heart failure (HF) hospitalization and improved quality life (QoL) vs placebo in patients stabilized following an acute HF (AHF) episode, no effect on cardiovascular (CV) death. Diabetes frequently accompany AHF. This post hoc analysis explored effects diabetes outcomes AFFIRM-AHF patients. Methods Patients were stratified by yes/no at baseline. The FCM primary (total...